<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MYKROX TABLETS- metolazoneÂ tabletÂ </strong><br>Celltech Pharmaceuticals, Inc.<br></p></div>
<h1>MykroxÂ® Tablets<br><br>(metolazone tablets, USP)</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold Underline">DO NOT INTERCHANGE:</span></p>
<p><span class="Bold">MYKROX TABLETS ARE A RAPIDLY AVAILABLE FORMULATION OF METOLAZONE FOR ORAL ADMINISTRATION. MYKROX TABLETS AND OTHER FORMULATIONS OF METOLAZONE THAT SHARE ITS MORE RAPID AND COMPLETE BIOAVAILABILITY ARE </span><span class="Bold Underline">NOT</span><span class="Bold"> THERAPEUTICALLY EQUIVALENT TO ZAROXOLYNÂ® TABLETS AND OTHER FORMULATIONS OF METOLAZONE THAT SHARE ITS SLOW AND INCOMPLETE BIOAVAILABILITY. FORMULATIONS BIOEQUIVALENT TO MYKROX AND FORMULATIONS BIOEQUIVALENT TO ZAROXOLYN SHOULD </span><span class="Bold Underline">NOT</span><span class="Bold"> BE INTERCHANGED FOR ONE ANOTHER.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">MYKROX Tablets (metolazone tablets, USP) for oral administration contain Â½ mg of metolazone, USP, a diuretic/saluretic/antihypertensive drug of the quinazoline class.</p>
<p>Metolazone has the molecular formula C<span class="Sub">16</span>H<span class="Sub">16</span>ClN<span class="Sub">3</span>O<span class="Sub">3</span>S, the chemical name 7-chloro-1, 2, 3, 4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide, and a molecular weight of 365.83. The structural formula is:</p>
<p><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dffb4544-0e47-40cd-9baa-d622075838cc&amp;name=mykrox-structure.jpg"></p>
<p>Metolazone is only sparingly soluble in water, but more soluble in plasma, blood, alkali, and organic solvents.</p>
<p>Inactive Ingredients: Dibasic calcium phosphate, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium starch glycolate. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">MYKROX (metolazone) is a quinazoline diuretic, with properties generally similar to the thiazide diuretics. The actions of MYKROX result from interference with the renal tubular mechanism of electrolyte reabsorption. MYKROX acts primarily to inhibit sodium reabsorption at the cortical diluting site and to a lesser extent in the proximal convoluted tubule. Sodium and chloride ions are excreted in approximately equivalent amounts. The increased delivery of sodium to the distal tubular exchange site results in increased potassium excretion. MYKROX does not inhibit carbonic anhydrase. A proximal action of metolazone has been shown in humans by increased excretion of phosphate and magnesium ions and by a markedly increased fractional excretion of sodium in patients with severely compromised glomerular filtration. This action has been demonstrated in animals by micropuncture studies. </p>
<p>The antihypertensive mechanism of action of metolazone is not fully understood but is presumed to be related to its saluretic and diuretic properties. </p>
<p>In two double-blind, controlled clinical trials of MYKROX Tablets, the maximum effect on mean blood pressure was achieved within 2 weeks of treatment and showed some evidence of an increased response at 1 mg compared to Â½ mg. There was no indication of an increased response with 2 mg. </p>
<p>After six weeks of treatment, the mean <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in serum potassium was 0.42 mEq/L at Â½ mg, 0.66 mEq/L at 1 mg, and 0.7 mEq/L at 2 mg. Serum <span class="product-label-link" type="condition" conceptid="4148593" conceptname="Blood urate raised">uric acid increased</span> by 1.1 to 1.4 mg/dL at increasing doses. There were small <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> in serum sodium and chloride and a 1.3-2.1 mg/dL increase in BUN at increasing doses.</p>
<p>The rate and extent of absorption of metolazone from MYKROX Tablets were equivalent to those from an oral solution of metolazone. Peak blood levels are obtained within 2 to 4 hours of oral administration with an elimination half-life of approximately 14 hours. MYKROX Tablets have been shown to produce blood levels that are dose proportional between Â½ -2 mg. Steady state blood levels are usually reached in 4-5 days. </p>
<p>In contrast, other formulations of metolazone produce peak blood concentrations approximately 8 hours following oral administration; absorption continues for an additional 12 hours.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">MYKROX Tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, alone or in combination with other antihypertensive drugs of a different class. </p>
<p><span class="Bold">MYKROX TABLETS HAVE </span><span class="Bold Underline">NOT</span><span class="Bold"> BEEN EVALUATED FOR THE TREATMENT OF <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span> OR <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">FLUID RETENTION</span> DUE TO RENAL OR <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">HEPATIC DISEASE</span> AND THE CORRECT DOSAGE FOR THESE CONDITIONS AND OTHER <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">EDEMA</span> STATES HAS NOT BEEN ESTABLISHED. </span></p>
<p><span class="Bold">SINCE A SAFE AND EFFECTIVE </span><span class="Bold Underline">DIURETIC</span><span class="Bold"> DOSE HAS NOT BEEN ESTABLISHED, MYKROX TABLETS SHOULD </span><span class="Bold Underline">NOT</span><span class="Bold"> BE USED WHEN <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">DIURESIS</span> IS DESIRED. </span></p>
<div class="Section" data-sectionCode="42228-7">
<a name="section-5.1"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First">The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of <span class="product-label-link" type="condition" conceptid="439393" conceptname="Pre-eclampsia">toxemia of pregnancy</span>, and there is no evidence that they are useful in the treatment of developed toxemia (see <a href="#Pre">PRECAUTIONS</a>).</p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. MYKROX is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> in pregnancy. <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">Dependent edema</span> in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span> during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span> which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, including <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, in the majority of pregnant women. If this <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> produces <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, increased recumbency will often provide relief. In rare instances, this <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> may cause extreme <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> which is not relieved by rest. In these cases, a short course of diuretics may be appropriate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">Anuria</span>, <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span> or <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">precoma</span>, known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to metolazone.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>Rapid Onset <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> and/or <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></h2>
<p class="First">Rarely, the rapid onset of severe <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and/or <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> has been reported following initial doses of thiazide and non-thiazide diuretics. When symptoms consistent with severe <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> appear rapidly, drug should be discontinued and supportive measures should be initiated immediately. Parenteral electrolytes may be required. Appropriateness of therapy with this class of drugs should be carefully reevaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="WarningsHypo"></a><a name="section-7.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may occur with consequent <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>. Serum potassium should be determined at regular and appropriate intervals, and dose reduction, potassium supplementation or addition of a potassium-sparing diuretic instituted whenever indicated. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> is a particular hazard in patients who are digitalized or who have or have had a <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>; dangerous or fatal <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> may be precipitated. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> is dose related.</p>
<p>In controlled clinical trials, 1.5% of patients taking Â½ mg and 3.1% of patients taking 1 mg of MYKROX daily developed clinical <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (defined as <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> accompanied by signs or symptoms); 21% of the patients taking Â½ mg and 30% of the patients taking 1 mg of MYKROX daily developed <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (defined as a serum potassium concentration below 3.5 mEq/L); in another controlled clinical trial in which the patients started therapy with a serum potassium level greater than 4.0 mEq/L, 8% of patients taking Â½ mg of MYKROX daily developed <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (defined as a serum potassium concentration below 3.5 mEq/L).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>Concomitant Therapy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1"></a><p></p>
<h3></h3>
<p class="First">Lithium</p>
<p>In general, diuretics should not be given concomitantly with lithium because they reduce its renal clearance and add a high risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Read prescribing information for lithium preparations before use of such concomitant therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.2"></a><p></p>
<h3></h3>
<p class="First">Furosemide</p>
<p>Unusually large or prolonged losses of fluids and electrolytes may result when metolazone is administered concomitantly to patients receiving furosemide (see <a href="#PreDI">PRECAUTIONS, Drug Interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.3"></a><p></p>
<h3></h3>
<p class="First">Other Antihypertensive Drugs</p>
<p>When MYKROX Tablets are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>Cross-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span></h2>
<p class="First">Cross-<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> may occur when MYKROX Tablets are given to patients known to be allergic to sulfonamide-derived drugs, thiazides, or quinethazone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2>Sensitivity Reactions</h2>
<p class="First">Sensitivity reactions (e.g., <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>) may occur with or without a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and may occur with the first dose of MYKROX. </p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Pre"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><span class="Bold Underline">DO NOT INTERCHANGE</span></p>
<p><span class="Bold">MYKROX TABLETS ARE A RAPIDLY AVAILABLE FORMULATION OF METOLAZONE FOR ORAL ADMINISTRATION. MYKROX TABLETS AND OTHER FORMULATIONS OF METOLAZONE THAT SHARE ITS MORE RAPID AND COMPLETE BIOAVAILABILITY ARE </span><span class="Bold Underline">NOT</span><span class="Bold"> THERAPEUTICALLY EQUIVALENT TO ZAROXOLYN TABLETS AND OTHER FORMULATIONS OF METOLAZONE THAT SHARE ITS SLOW AND INCOMPLETE BIOAVAILABILITY. FORMULATIONS BIOEQUIVALENT TO MYKROX AND FORMULATIONS BIOEQUIVALENT TO ZAROXOLYN SHOULD </span><span class="Bold Underline">NOT</span><span class="Bold"> BE INTERCHANGED FOR ONE ANOTHER.</span></p>
<div class="Section" data-sectionCode="34072-9">
<a name="section-8.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<h3></h3>
<p class="First">Fluid and Electrolytes</p>
<p>All patients receiving therapy with MYKROX Tablets should have serum electrolyte measurements done at appropriate intervals and be observed for clinical signs of fluid and/or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>: namely, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. In patients with severe <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> accompanying <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, a low-salt syndrome may be produced, especially with hot weather and a low-salt diet. Serum and urine electrolyte determinations are particularly important when the patient has protracted <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or is receiving parenteral fluids. Warning signs of imbalance are: dryness of mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="4214612" conceptname="Muscle fatigue">muscle fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> may occur at any time during long term therapy and, on rare occasions, may be life threatening.</p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> is increased when larger doses are used, when <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> is rapid, when severe liver disease is present, when corticosteroids are given concomitantly, when oral intake is inadequate or when excess potassium is being lost extrarenally, such as with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>Thiazide-like diuretics have been shown to increase the urinary excretion of magnesium; this may result in <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="PreGenGT"></a><a name="section-8.1.2"></a><p></p>
<h3></h3>
<p class="First">Glucose Tolerance</p>
<p>Metolazone may raise blood glucose concentrations possibly causing <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span> in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.3"></a><p></p>
<h3></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span></p>
<p>MYKROX regularly causes an increase in serum uric acid and can occasionally precipitate gouty attacks even in patients without a prior history of them.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.4"></a><p></p>
<h3></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">Azotemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">Azotemia</span>, presumably prerenal <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, may be precipitated during the administration of MYKROX Tablets. If <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> and <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> worsen during treatment of patients with severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, MYKROX Tablets should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.5"></a><p></p>
<h3></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></p>
<p>Use caution when administering MYKROX Tablets to patients with severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. As most of the drug is excreted by the renal route, accumulation may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.6"></a><p></p>
<h3></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></p>
<p><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> may occur; this may be potentiated by alcohol, barbiturates, narcotics, or concurrent therapy with other antihypertensive drugs. In controlled clinical trials, 1.4% of patients treated with MYKROX Tablets (Â½ mg) had <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>; this effect was not reported in the placebo group. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.7"></a><p></p>
<h3></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> may infrequently occur with metolazone, especially in patients taking high doses of vitamin D or with high bone turnover states, and may signify hidden <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span>. Metolazone should be discontinued before tests for parathyroid function are performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.8"></a><p></p>
<h3></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic Lupus Erythematosus</span></p>
<p>Thiazide diuretics have exacerbated or activated <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> and this possibility should be considered with MYKROX Tablets.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be informed of possible adverse effects, advised to take the medication as directed, and promptly report any possible adverse reactions to the treating physician.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="PreDI"></a><a name="section-8.3"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.1"></a><p></p>
<h3></h3>
<p class="First">Diuretics</p>
<p>Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes (see <a href="#Warnings">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.2"></a><p></p>
<h3></h3>
<p class="First">Other Antihypertensives</p>
<p>When MYKROX Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy. Dosage adjustments of other antihypertensives may be necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.3"></a><p></p>
<h3></h3>
<p class="First">Alcohol, Barbiturates, and Narcotics</p>
<p>The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.4"></a><p></p>
<h3></h3>
<p class="First">Digitalis Glycosides</p>
<p>Diuretic-induced <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> can increase the sensitivity of the myocardium to digitalis. Serious <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> can result.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.5"></a><p></p>
<h3></h3>
<p class="First">Corticosteroids or ACTH</p>
<p>May increase the risk of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and increase salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.6"></a><p></p>
<h3></h3>
<p class="First">Lithium</p>
<p>Serum lithium levels may increase (see <a href="#Warnings">WARNINGS</a>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.7"></a><p></p>
<h3></h3>
<p class="First">Curariform Drugs</p>
<p>Diuretic-induced <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) â€“ the most serious effect would be <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> which could proceed to <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>. Accordingly, it may be advisable to discontinue MYKROXÂ® Tablets (metolazone tablets, USP) three days before elective surgery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.8"></a><p></p>
<h3></h3>
<p class="First">Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs</p>
<p>May decrease the antihypertensive effects of MYKROX Tablets. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.9"></a><p></p>
<h3></h3>
<p class="First">Sympathomimetics</p>
<p>Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.10"></a><p></p>
<h3></h3>
<p class="First">Insulin and Oral Antidiabetic Agents</p>
<p>See <a href="http://PreGenGT">Glucose Tolerance</a> under PRECAUTIONS, General. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.11"></a><p></p>
<h3></h3>
<p class="First">Methenamine</p>
<p>Efficacy may be decreased due to urinary alkalizing effect of metolazone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3.12"></a><p></p>
<h3></h3>
<p class="First">Anticoagulants</p>
<p>Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants; dosage adjustments may be necessary.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-8.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">None reported.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Mice and rats administered metolazone 5 days/week for up to 18 and 24 months, respectively, at daily doses of 2, 10, and 50 mg/kg, exhibited no evidence of a tumorigenic effect of the drug. The small number of animals examined histologically and poor survival in the mice limit the conclusions that can be reached from these studies. </p>
<p>Metolazone was not mutagenic <span class="Italics">in vitro</span> in the Ames Test using <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA-97, TA-98, TA-100, TA-102, and TA-1535. </p>
<p>Reproductive performance has been evaluated in mice and rats. There is no evidence that metolazone possesses the potential for altering reproductive capacity in mice. In a rat study, in which males were treated orally with metolazone at doses of 2, 10, and 50 mg/kg for 127 days prior to mating with untreated females, an increased number of resorption sites was observed in dams mated with males from the 50 mg/kg group. In addition, the birth weight of offspring was decreased and the pregnancy rate was reduced in dams mated with males from the 10 and 50 mg/kg groups. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.6.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.1.1"></a><p></p>
<h4><span class="Italics">Pregnancy Category B</span></h4>
<p class="First">Reproduction studies performed in mice, rabbits, and rats treated during the appropriate period of gestation at doses up to 50 mg/kg/day have revealed no evidence of harm to the fetus due to metolazone. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, MYKROX Tablets should be used during pregnancy only if clearly needed. Metolazone crosses the placental barrier and appears in cord blood.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-8.6.2"></a><p></p>
<h3>Non-Teratogenic Effects</h3>
<p class="First">The use of MYKROX Tablets in pregnant women requires that the anticipated benefit be weighed against possible hazards to the fetus. These hazards include fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly other adverse reactions which have occurred in the adult. It is not known what effect the use of the drug during pregnancy has on the later growth, development, and functional maturation of the child. No such effects have been reported with metolazone. </p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-8.7"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">Based on clinical studies in which women received metolazone in late pregnancy until the time of delivery, there is no evidence that the drug has any adverse effects on the normal course of labor or delivery.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Metolazone appears in breast milk. Because of the potential for serious adverse reactions in nursing infants from metolazone, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness of MYKROX Tablets in pediatric patients have not been established, and such use is not recommended. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of MYKROX did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. </p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse experience information is available from more than 14 years of accumulated marketing experience with other formulations of metolazone for which reliable quantitative information is lacking and from controlled clinical trials with MYKROX from which incidences can be calculated. </p>
<p>In controlled clinical trials with MYKROX, adverse experiences resulted in discontinuation of therapy in 6.7-6.8% of patients given Â½ to 1 mg of MYKROX.</p>
<p>Adverse experiences occurring in controlled clinical trials with MYKROX with an incidence of &gt;2%, whether or not considered drug-related, are summarized in the following table.</p>
<table width="90%">
<caption><span>Incidence of Adverse Experiences Volunteered or Elicited (by Patient in Percent)*</span></caption>
<col align="left">
<col align="center">
<tfoot>
<tr class="First"><td align="left" colspan="2">* Percent of patients reporting an adverse experience one or more times.</td></tr>
<tr class="Last"><td align="left" colspan="2">â€  All doses combined (Â½, 1, and 2 mg).</td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td align="left"></td>
<td align="center">
<span class="Bold">MYKROX</span><br><br><span class="Bold Underline">n = 226â€ </span>
</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> (<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>)</span></td>
<td align="center">10.2</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span> </span></td>
<td align="center">9.3</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle Cramps</span></span></td>
<td align="center">5.8</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> (<span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>)</span></td>
<td align="center">4.4</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Joint Pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></span></td>
<td align="center">3.1</td>
</tr>
<tr class="Last">
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span> (precordial <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>)</span></td>
<td align="center">2.7</td>
</tr>
</tbody>
</table>
<p>Some of the adverse effects reported in association with MYKROX also occur frequently in untreated hypertensive patients, such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, which occurred in 14.8 and 7.4% of patients in a smaller parallel placebo group.</p>
<p>The following adverse effects were reported in less than 2% of the MYKROX treated patients.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Cardiovascular</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">Cold extremities</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Central and Peripheral Nervous System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, â€œweirdâ€? feeling.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.3"></a><p></p>
<h2>Dermatological</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, skin dryness.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.4"></a><p></p>
<h2>Eyes, Ears, Nose, Throat</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">eye itching</span>, <span class="product-label-link" type="condition" conceptid="4220211" conceptname="Congestion of nasal sinus">sinus congestion</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.5"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>), bitter taste, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.6"></a><p></p>
<h2>Genitourinary</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">Nocturia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.7"></a><p></p>
<h2>Musculoskeletal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.8"></a><p></p>
<h2>Other Adverse Experiences</h2>
<p class="First">Adverse experiences reported with other marketed metolazone formulations and most thiazide diuretics, for which quantitative data are not available, are listed in decreasing order of severity within body systems. Several are single or rare occurrences.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.8.1"></a><p></p>
<h3></h3>
<p class="First">Cardiovascular</p>
<p>excessive <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, hemoconcentration, <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.8.2"></a><p></p>
<h3></h3>
<p class="First">Central and Peripheral Nervous System</p>
<p><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> (sometimes resulting in <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.8.3"></a><p></p>
<h3></h3>
<p class="First">Dermatologic/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></p>
<p><span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span> (<span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>), <span class="product-label-link" type="condition" conceptid="4317266" conceptname="Skin necrosis">skin necrosis</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.8.4"></a><p></p>
<h3></h3>
<p class="First">Gastrointestinal</p>
<p><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.8.5"></a><p></p>
<h3></h3>
<p class="First">Hematologic</p>
<p>aplastic (hypoplastic) <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.8.6"></a><p></p>
<h3></h3>
<p class="First">Metabolic</p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (see <a href="#WarningsHypo">WARNINGS, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></a>), <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, increase in serum urea nitrogen (BUN) or creatinine, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.8.7"></a><p></p>
<h3></h3>
<p class="First">Musculoskeletal</p>
<p>acute gouty attacks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.8.8"></a><p></p>
<h3></h3>
<p class="First">Other</p>
<p>transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>.</p>
<p>In addition, rare adverse experiences reported in association with similar antihypertensive-diuretics but not reported to date for metolazone include: <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>, <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> (including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>), and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>. These experiences could occur with clinical use of metolazone.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Intentional overdosage has been reported rarely with metolazone and similar diuretic drugs.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, electrolyte abnormalities, hemoconcentration and hemodynamic changes due to plasma <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> may occur. In some instances depressed respiration may be observed. At high doses, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> of varying degree may progress to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> within a few hours. The mechanism of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> with thiazide overdosage is unknown. Also, <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">GI irritation</span> and hypermotility may occur. Temporary elevation of BUN has been reported, especially in patients with impairment of renal function. Serum electrolyte changes and cardiovascular and renal function should be closely monitored. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">There is no specific antidote available but immediate evacuation of stomach contents is advised. Dialysis is not likely to be effective. Care should be taken when evacuating the gastric contents to prevent <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>, especially in the stuporous or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">comatose</span> patient. Supportive measures should be initiated as required to maintain hydration, electrolyte balance, respiration, and cardiovascular and renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Therapy should be individualized according to patient response.</p>
<p>For initial treatment of mild to moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, the recommended dose is one MYKROX Tablet (Â½ mg) once daily, usually in the morning. If patients are inadequately controlled with one Â½ mg tablet, the dose can be increased to two MYKROX Tablets (1 mg) once a day. An increase in <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may occur. Doses larger than 1 mg do not give increased effectiveness.</p>
<p>The same dose titration is necessary if MYKROX Tablets are to be substituted for other dosage forms of metolazone in the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p>If blood pressure is not adequately controlled with two MYKROX Tablets alone, the dose should not be increased; rather, another antihypertensive agent with a different mechanism of action should be added to therapy with MYKROX Tablets.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">MYKROX Tablets (metolazone tablets, USP), Â½ mg are white, flat-faced, round tablets, debossed â€œMYKROXâ€? on one side, and â€œÂ½â€? on reverse side.</p>
<p>NDC 53014-847-71Â Â Â Â Â Â Â Â Bottle of 100â€™s </p>
<p>Store at 25Â°C (77Â°F); excursions permitted to 15Â°-30Â°C (59Â°-86Â°F) [See USP Controlled Room Temperature]. Protect from light. Keep out of the reach of children.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Celltech Pharmaceuticals, Inc.</span><br><br>Rochester, NY 14623  USA </p>
<p>Â® Celltech Manufacturing, Inc.<br><br>Â© 2003, Celltech Pharmaceuticals, Inc.<br><br>All rights reserved.</p>
<p>Rev. 2/03<br><br>R528B</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MYKROX TABLETSÂ 		
					</strong><br><span class="contentTableReg">metolazone tablets tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">53014-847</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>metolazone</strong> (metolazone) </td>
<td class="formItem"></td>
<td class="formItem">500Â ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>dibasic calcium phosphate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>microcrystalline cellulose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>pregelatinized starch</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MYKROX;1/2</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53014-847-71</td>
<td class="formItem">100  in  BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Celltech Pharmaceuticals, Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>dffb4544-0e47-40cd-9baa-d622075838cc</div>
<div>Set id: dffb4544-0e47-40cd-9baa-d622075838cc</div>
<div>Version: 1</div>
<div>Effective Time: 20060112</div>
</div>
</div>Â <div class="DistributorName">Celltech Pharmaceuticals, Inc.</div></p>
</body></html>
